Q2 2022 13F Holders as of 6/30/2022
-
Type / Class
-
Equity / Common stock ("Common Shares")
-
Shares outstanding
-
213M
-
Number of holders
-
120
-
Total 13F shares, excl. options
-
44.2M
-
Shares change
-
+974K
-
Total reported value, excl. options
-
$178M
-
Value change
-
+$2.78M
-
Put/Call ratio
-
0.4
-
Number of buys
-
55
-
Number of sells
-
-54
-
Price
-
$4.02
Significant Holders of OCULAR THERAPEUTIX, INC - Common stock ("Common Shares") (OCUL) as of Q2 2022
145 filings reported holding OCUL - OCULAR THERAPEUTIX, INC - Common stock ("Common Shares") as of Q2 2022.
OCULAR THERAPEUTIX, INC - Common stock ("Common Shares") (OCUL) has 120 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 44.2M shares
of 213M outstanding shares and own 20.76% of the company stock.
Largest 10 shareholders include Opaleye Management Inc. (5.97M shares), SUMMER ROAD LLC (5.94M shares), BlackRock Inc. (4.8M shares), VANGUARD GROUP INC (3.9M shares), DELTEC ASSET MANAGEMENT LLC (2.07M shares), CITADEL ADVISORS LLC (1.72M shares), EMERALD ADVISERS, LLC (1.47M shares), STATE STREET CORP (1.41M shares), GEODE CAPITAL MANAGEMENT, LLC (1.35M shares), and FEDERATED HERMES, INC. (1.19M shares).
This table shows the top 120 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.